SuperGen to present SGI-110 data for MDS, AML at ASH annual meeting

SuperGen, Inc. (NASDAQ:SUPG) today announced that a summary of preclinical efficacy, safety, and pharmacokinetics data of SGI-110 will be presented at the American Society of Hematology in Orlando on Saturday, December 4, 2010 at 5:30 pm ET. The title of the poster presentation will be "SGI-110, a novel second generation potent DNA methylation inhibitor, in development for the treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA methylation results of a low volume subcutaneous (SC) formulation."

“SGI-110, a novel second generation potent DNA methylation inhibitor, in development for the treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA methylation results of a low volume subcutaneous (SC) formulation.”

SGI-110 has received clearance from the Food and Drug Administration to advance into Phase I trials. The clinical trial has been initiated at MD Anderson Cancer Center and other centers are being initiated.

"SGI-110 is a low volume, easy to administer, subcutaneous drug with a pre-clinical profile that has demonstrated potent hypomethylation and epigenetic modulation with less frequent administration than currently marketed hypomethylating agents," said Mohammad Azab, M.D., Chief Medical Officer. "Its preclinical anticancer and hypomethylating effects have been observed in both hematological and solid tumors models."